Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

NCT06246110 is registered in ClinicalTrials.gov with Eikon Therapeutics as lead sponsor.

NCT NCT06246110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06246110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
Lead sponsor
Eikon Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 6, 2024
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc